Jason P. Lynch

Brisbane, QLD 4006, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Development and characterization of AD-214, an anti-CXCR4 i-body-Fc fusion for the treatment of idiopathic pulmonary fibrosis.

Development and characterization of AD-214, an anti-CXCR4 i-body-Fc fusion for the treatment of idiopathic pulmonary fibrosis.

Journal: mAbs

Published: May 21, 2025

In situ deposition of nanobodies by an engineered commensal microbe promotes survival in a mouse model of enterohemorrhagic E. coli.

In situ deposition of nanobodies by an engineered commensal microbe promotes survival in a mouse model of enterohemorrhagic E. coli.

Journal: bioRxiv : the preprint server for biology

Published: August 12, 2024

In situ deposition of nanobodies by an engineered commensal microbe promotes survival in a mouse model of enterohemorrhagic E. coli.

In situ deposition of nanobodies by an engineered commensal microbe promotes survival in a mouse model of enterohemorrhagic E. coli.

Journal: PNAS nexus

Published: July 23, 2024

PROT3EcT, engineered Escherichia coli for the targeted delivery of therapeutics.

PROT3EcT, engineered Escherichia coli for the targeted delivery of therapeutics.

Journal: Trends in molecular medicine

Published: June 21, 2023

Maternal diet modulates the infant microbiome and intestinal Flt3L necessary for dendritic cell development and immunity to respiratory infection.

Maternal diet modulates the infant microbiome and intestinal Flt3L necessary for dendritic cell development and immunity to respiratory infection.

Journal: Immunity

Published: July 19, 2022

Engineered Escherichia coli for the in situ secretion of therapeutic nanobodies in the gut.

Engineered Escherichia coli for the in situ secretion of therapeutic nanobodies in the gut.

Journal: Cell host & microbe

Published: June 09, 2022

Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics.

Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics.

Journal: Trends in pharmacological sciences

Published: December 16, 2021

Targeting the P2Y13 Receptor Suppresses IL-33 and HMGB1 Release and Ameliorates Experimental Asthma.

Targeting the P2Y13 Receptor Suppresses IL-33 and HMGB1 Release and Ameliorates Experimental Asthma.

Journal: American journal of respiratory and critical care medicine

Published: December 03, 2021

Synthetic biology: at the crossroads of genetic engineering and human therapeutics-a Keystone Symposia report.

Synthetic biology: at the crossroads of genetic engineering and human therapeutics-a Keystone Symposia report.

Journal: Annals of the New York Academy of Sciences

Published: October 05, 2021

Bone Marrow Regulatory T Cells Are a Unique Population, Supported by Niche-Specific Cytokines and Plasmacytoid Dendritic Cells, and Required for Chronic Graft-Versus-Host Disease Control.

Bone Marrow Regulatory T Cells Are a Unique Population, Supported by Niche-Specific Cytokines and Plasmacytoid Dendritic Cells, and Required for Chronic Graft-Versus-Host Disease Control.

Journal: Frontiers in cell and developmental biology

Published: July 07, 2021

A host metabolite promotes Salmonella survival.

A host metabolite promotes Salmonella survival.

Journal: Science (New York, N.Y.)

Published: January 22, 2021

HMGB1 amplifies ILC2-induced type-2 inflammation and airway smooth muscle remodelling.

HMGB1 amplifies ILC2-induced type-2 inflammation and airway smooth muscle remodelling.

Journal: PLoS pathogens

Published: March 10, 2020

Showing 1-12 of 28

Last Updated: 09/26/2026